Insulin glargine

Clinical Therapeutics

Volumn 23, Issue 12, 2001, Pages 1938-1957

  Campbell, R Keith ^a   White, John R ^b   Levien, Terri ^b   Baker, Danial ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Diabetes mellitus; Insulin analogue; Insulin glargine

Indexed keywords

INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LENTE; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MIXTURE; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MEDICAL LITERATURE; MEDLINE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PEER REVIEW; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0035690595     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80148-X     Document Type: Article

References (50)

1. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas
2. Improving insulin therapy: Achievements and challenges
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. Insulin analogues: New agents for improving glycemic control
6. Nocturnal blood glucose control in type I diabetes mellitus
7. Clinical pharmacology of human insulin
8. Pharmacokinetics of long-acting (ultralente) insulin preparations
9. Insulin pharmacokinetics
10. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes
11. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
12. Controlling insulin bioavailability by crystal contact engineering
13. HOE901: A new insulin with prolonged action
14. Insulin analogues
15. New insulin preparations with prolonged action profiles: A21-modified arginine insulins
16. Long-acting insulin analogs
17. Insulin analogues and their potential in the management of diabetes mellitus
18. The long acting human insulin analog HOE 901: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin
19. IGF-I Receptor-mediated signalling of the human insulin analogue HOE 901
20. B32]insulin (HOE 901) in muscle cells
21. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
22. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation
23. Pharmacodynamics of s.c. injection of the long-acting insulin glargine (HOE901) in T1DM
24. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro
25. 125I-labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites
26. Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31 ,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using eugly-cemic clamp technique
27. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo
28. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique
29. Comparison of the sc absorption of HOE901 and NPH insulin type 2 diabetic subjects
30. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
31. The effect of HOE 901 on glycemic control in type 2 diabetes
32. Comparative clinical trial of a new long-acting insulin (HOE901) vs protamine insulin demonstrates less nocturnal hypoglycemia
33. Comparison of insulin glargine (HOE 901) and NPH insulin in intensified therapy of type 1 diabetics: Results of an international, multicenter, randomized 28-week study
34. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes
35. Insulin glargine (HOE901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing risk of hypoglycemia
36. Results of a 12-month study: Insulin glargine (HOE 901)in combination with oral agents
37. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin
38. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
39. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes
40. Treatment satisfaction and psychological well-being in patients with type 1 diabetes treated with a new long-acting insulin, insulin glargine
41. The Diabetes Treatment Satisfaction Questionnaire: DTSQ
42. The well-being questionnaire
43. Improved psychological outcomes after initiation of insulin treatment in patients with type 2 diabetes
44. Safety of insulin glargine